Clinical trial
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a…
NCT00165399 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165399 |
|---|---|
| Title | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment |
| Official title | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Estramustine, Casodex, Zoladex |
| Enrollment | 62 |
| Start date | Mar 1, 2004 |
| Primary completion | Dec 31, 2005 |
| Completion | Dec 31, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Jun 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: